These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 31334593)

  • 21. Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature.
    Diaz-Ramos A; Eilbert W; Marquez D
    Int J Emerg Med; 2019 Sep; 12(1):27. PubMed ID: 31488052
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Self-Induced Euglycemic Diabetic Ketoacidosis: When to Stop the Drip.
    Zughaib MT; Patel K; Leka M; Affas S
    Cureus; 2022 Jan; 14(1):e21768. PubMed ID: 35251838
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Canagliflozin use in Type I diabetes mellitus.
    Guthrie R
    Postgrad Med; 2017 Apr; 129(3):336-339. PubMed ID: 27918226
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sodium-glucose co-transporter-2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: A nationwide population-based cohort study.
    Kim YG; Jeon JY; Han SJ; Kim DJ; Lee KW; Kim HJ
    Diabetes Obes Metab; 2018 Aug; 20(8):1852-1858. PubMed ID: 29569427
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care.
    Danne T; Biester T; Kordonouri O
    Diabetes Technol Ther; 2018 Jun; 20(S2):S269-S277. PubMed ID: 29916741
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Euglycaemic diabetic ketoacidosis in a patient with type 2 diabetes started on empagliflozin.
    Rashid O; Farooq S; Kiran Z; Islam N
    BMJ Case Rep; 2016 May; 2016():. PubMed ID: 27177938
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Literature Review of the Therapeutic Perspectives of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor-Induced Euglycemic Diabetic Ketoacidosis.
    Patel K; Nair A
    Cureus; 2022 Sep; 14(9):e29652. PubMed ID: 36320965
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ketoacidosis Due to Empagliflozin, a Paradigm Shift: Case Report and Review of Literature.
    Hernandez-Quiles C; Ramirez-Duque N; Acosta-Delgado D
    Curr Diabetes Rev; 2019; 15(4):259-262. PubMed ID: 30047331
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical characteristics of diabetic ketoacidosis in users and non-users of SGLT2 inhibitors.
    Jeon JY; Kim SK; Kim KS; Song SO; Yun JS; Kim BY; Kim CH; Park SO; Hong S; Seo DH; Seo JA; Noh JH; Kim DJ;
    Diabetes Metab; 2019 Oct; 45(5):453-457. PubMed ID: 30639566
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Euglycemic Diabetic Ketoacidosis in a 27 year-old female patient with type-1-Diabetes treated with sodium-glucose cotransporter-2 (SGLT2) inhibitor Canagliflozin.
    Bader N; Mirza L
    Pak J Med Sci; 2016; 32(3):786-8. PubMed ID: 27375734
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 Canagliflozin.
    Kelmenson DA; Burr K; Azhar Y; Reynolds P; Baker CA; Rasouli N
    J Investig Med High Impact Case Rep; 2017; 5(2):2324709617712736. PubMed ID: 28634592
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SGLT-2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis: A Case Report and a Literature Review.
    Mahfooz RS; Khan MK; Al Hennawi H; Khedr A
    Cureus; 2022 Jun; 14(6):e26267. PubMed ID: 35911365
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Beyond type 2 diabetes: sodium glucose co-transporter-inhibition in type 1 diabetes.
    Biester T; Kordonouri O; Danne T
    Diabetes Obes Metab; 2019 Apr; 21 Suppl 2():53-61. PubMed ID: 31081591
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hyperglycemic, high anion-gap metabolic acidosis in patients receiving SGLT-2 inhibitors for diabetes management.
    Kum-Nji JS; Gosmanov AR; Steinberg H; Dagogo-Jack S
    J Diabetes Complications; 2017 Mar; 31(3):611-614. PubMed ID: 27913012
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Empagliflozin-Associated Euglycemic Diabetic Ketoacidosis in a Patient With Type 2 Diabetes Mellitus.
    Chauhan S; Manov A; Dhillon GS; Shah P
    Cureus; 2023 Jan; 15(1):e33892. PubMed ID: 36819400
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [SGLT 2 inhibitors in Type 1 diabetes].
    Stougaard EB; Amadid H; Søndergaard E; Jørgensen ME; Persson F; Rossing P
    Ugeskr Laeger; 2020 Aug; 182(35):. PubMed ID: 32829747
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sodium-Glucose Transporter Inhibition in Adult and Pediatric Patients with Type 1 Diabetes Mellitus.
    Vitale RJ; Laffel LM
    Adv Chronic Kidney Dis; 2021 Jul; 28(4):309-317. PubMed ID: 34922687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Euglycemic Diabetic Ketoacidosis: A Review.
    Modi A; Agrawal A; Morgan F
    Curr Diabetes Rev; 2017; 13(3):315-321. PubMed ID: 27097605
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The DKA that wasn't: a case of euglycemic diabetic ketoacidosis due to empagliflozin.
    Candelario N; Wykretowicz J
    Oxf Med Case Reports; 2016 Jul; 2016(7):144-6. PubMed ID: 27471597
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SGLT2 Inhibition by Dapagliflozin Attenuates Diabetic Ketoacidosis in Mice with Type-1 Diabetes.
    Chen H; Birnbaum Y; Ye R; Yang HC; Bajaj M; Ye Y
    Cardiovasc Drugs Ther; 2022 Dec; 36(6):1091-1108. PubMed ID: 34448973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.